Will pharmacogenomic testing become a routine part of clinical care?

Some adverse drug events are a predictable consequence of therapeutic, especially dosing failures. Idiosyncratic toxicities, on the other hand, are much less predictable and much more insidious. Pharmacogenomics is a powerful tool that can reveal some of these vulnerabilities before toxicity occurs or, if performed after the fact, can explain the cause of an adverse drug event that has already happened. Clinical trials cannot detect all adverse drug events due to the limited population in which the drugs are being

Read More »

Subscribe to our newsletter